IMRN News and Press, Immuron Limited From 09/06/22

Immuron Limited (IMRN) Q4 2022 Earnings Conference Call September 6, 2022, 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive Officer Conference Call Participants Presentation Unidentified Company Representative Good morning, e...

MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast ...

Immuron ( NASDAQ: IMRN ) said it has deprioritized SARS-CoV-2 research to focus on clinical development of its more advanced stage therapeutic drug candidates. The Australian company added that it dedicated significant resources to investigate the mechanism of novel co...

MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized...

The U.S. Food and Drug Administration placed a clinical hold on the start of trials of an oral antibacterial drug, noting insufficient information in the investigational new drug  (IND) application. Australia-based Immuron ( NASDAQ: IMRN ) said that the US Na...

MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US ...

Immuron ( NASDAQ: IMRN ) announces North America, Travelan sales were up by 494%, reaching AU $0.6M in FY22, compared to AU $0.1M in FY21. Global sales of Travelan and Protectyn increased by 431% in the 2022 fiscal year to AU $0.9M, compared to AU $0.2M in FY21. In th...

Highlights: North American FY22 Travelan® sales increased by +494% to $0.6M Global sales increased by 431% to $0.9M Australian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:...

Immuron ( NASDAQ: IMRN ) said the European Patent Office intends to grant the company a patent related to compositions and methods for treatment and/or preventing diseases due to the bacterium Clostridioides difficile. Clostridioides difficile infection is a disea...

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...